Modeling the impact of screening policy and screening compliance on incidence and mortality of cervical cancer in the post-HPV vaccination era

Journal of Public Health (United Kingdom)

Volumn 34, Issue 4, 2012, Pages 539-547

  De Blasio, Birgitte Freiesleben ^a,b   Neilson, Aileen Rae ^c   Klemp, Marianne ^c   Skjeldestad, Finn Egil ^b,d  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

Author keywords

cervical cancer; health impact assessment; HPV vaccination; screening

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COST CONTROL; DISEASE TRANSMISSION; EARLY DIAGNOSIS; ECONOMICS; FEMALE; HEALTH CARE POLICY; HOSPITAL MANAGEMENT; HUMAN; INCIDENCE; METHODOLOGY; MIDDLE AGED; NORWAY; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PATIENT ATTITUDE; STANDARD; STATISTICS; THEORETICAL MODEL; TIME; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADULT; AGE DISTRIBUTION; AGED; APPOINTMENTS AND SCHEDULES; COST SAVINGS; EARLY DETECTION OF CANCER; FEMALE; HEALTH POLICY; HUMANS; INCIDENCE; MIDDLE AGED; MODELS, THEORETICAL; NORWAY; OUTCOME ASSESSMENT (HEALTH CARE); PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84870176375     PISSN: 17413842     EISSN: 17413850     Source Type: Journal    
DOI: 10.1093/pubmed/fds040     Document Type: Article

References (32)

1. Lowy DR, Solomon D, Hildesheim A et al. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 2008;113:1980-93.
2. Nygard JF, Skare GB, Thoresen SO. The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen 2002;9:86-91. (Pubitemid 34822870)
3. D'Andrilli G, Bovicelli A, Giordano A. HPV vaccines: state of the art. J Cell Physiol 2010;224:601-4.
4. Schmiedeskamp MR, Kockler DR. Human papillomavirus vaccines. Ann. Pharmacother 2006;40:1344-52. (Pubitemid 44204965)
5. Kulasingam SL, Pagliusi S, Myers E. Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. Vaccine 2007;25:8110-13. (Pubitemid 350046322)
6. Panagopoulou E, Giata O, Montgomery A et al. Human papillomavirus and cervical screening: misconceptions undermine adherence. Am J Health Promot 2011;26:6-9.
7. Franco EL, Mahmud SM, Tota J et al. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res 2009;40:478-85.
8. Gravitt PE, Belinson JL, Salmeron J et al. Looking ahead: a case for HPV testing of self-sampled vaginal specimens as a cervical cancer screening strategy. Int J Cancer 2011;129(3):517-27.
9. Leinonen M, Nieminen P, Kotaniemi-Talonen L et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009;101:1612-23.
10. Neilson AR, de Blasio BF. Cost-effectiveness of human papillomavirus (HPV) vaccination in Norway. 12-2007. Oslo, Norway: Norwegian Knowledge Centre for the Health Services, 2007, 1-68.
11. de Blasio BF, Neilson AR, Gjertsen MK. Estimating uncertainties of HPV16/18 vaccination - a dynamic modelling approach. 17-2008. Oslo, Norway: Norwegian Knowledge Centre for the Health Services, 2008, 1-33.
12. Zechmeister I, de Blasio BF, Garnett G et al. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 2009;27:5133-41.
13. Zechmeister I, de Blasio BF, Garnett GP. HPV vaccination for the prevention of cervical cancer in Austria: a model based long-term prognosis of cancer epidemiology. J Public Health 2010;18:3-13.
14. Choi YH, Jit M, Gay N et al. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 2010;28:4091-102.
15. Kim JJ, Brisson M, Edmunds WJ et al. Modeling cervical cancer prevention in developed countries. Vaccine 2008;26(Suppl. 10):K76-86.
16. Sawaya GF, Grady D, Kerlikowske K et al. The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS). Ann Intern Med 2000;133:942-50. (Pubitemid 32003510)
17. Tay K, Tay SK. The impact of cytology screening and HPV vaccination on the burden of cervical cancer. Asia Pac J Clin Oncol 2011;7:154-9.
18. Sopina E, Ashton T. Cost-effectiveness of a cervical screening program with human papillomavirus vaccine. Int J Technol Assess Health Care 2011;27:290-7.
19. Sroczynski G, Schnell-Inderst P, Muhlberger N et al. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. GMS Health Technol Assess 2010;6:1-13.
20. Van de Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007;165:762-75. (Pubitemid 46434599)
21. Kim JJ, Kuntz KM, Stout NK et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007;166:137-50. (Pubitemid 47227293)
22. Ho GY, Bierman R, Beardsley L et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8. (Pubitemid 28135669)
23. Woodman CB, Collins S, Winter H et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-6. (Pubitemid 32539115)
24. Skjeldestad FE, Mehta V, Sings HL et al. Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics. Acta Obstet Gynecol Scand 2008;87:81-8.
25. Kitchener HC, Almonte M, Wheeler P et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006;95:56-61. (Pubitemid 43980554)
26. Forslund O, Antonsson A, Edlund K et al. Population-based typespecific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol 2002;66:535-41. (Pubitemid 34203245)
27. Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis 2009;9:119.
28. Bjøge T, Thoresen SO, Skare GB. Incidence, survival and mortality in cervical cancer in Norway, 1956-1990. Eur J Cancer 1993;29:2291-7. (Pubitemid 24053010)
29. Johansen BK, Skare GB, Halrdorsen T et al. Å rsrapport 2008: Masseundersøelsen mot livmorhalskreft. Norwegian Cancer Registry, 2008,1-58.
30. Castle PE, Stoler MH, Wright TC et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011; 12:880-90.
31. Coste J, Cochand-Priollet B, de Cremoux P et al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ 2003;326:733-36. (Pubitemid 36408038)
32. Træn B, Stigum H, Magnus P. Rapport fra Seksualvaneunder seølsene. 12-5-2010. Oslo, Norway: Norwegian Institute of Public Health, 2003.